THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about this circular or as to the action to be taken, you should consult your stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Jinxin Fertility Group Limited, you should at once hand this circular to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS
(2) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES
(3) DECLARATION OF FINAL DIVIDEND
(4) PROPOSED RE-APPOINTMENT OF AUDITOR
AND
(5) NOTICE OF ANNUAL GENERAL MEETING

A notice convening the Annual General Meeting of Jinxin Fertility Group Limited to be held at Conference Room No. 3, 5th Floor, Chengdu Xinan Gynecology Hospital, 66 Bisheng Road, Jinjiang District, Chengdu, Sichuan, China on Thursday, June 25, 2026 at 9:00 a.m. is set out on pages AGM-1 to AGM-5 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.jxr-fertility.com).

Whether or not you are able to attend the Annual General Meeting, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event no less than 48 hours before the time appointed for the holding of the Annual General Meeting (i.e. before 9:00 a.m. on Tuesday, June 23, 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude shareholders from attending and voting in person at the Annual General Meeting (or any adjournment thereof) should you so wish.

Holders of treasury Shares, if any, have no voting rights at the general meeting(s) of the Company.

June 2, 2026

* *For identification purpose only*

CONTENTS

Page

DEFINITIONS 1

LETTER FROM THE BOARD

1. INTRODUCTION 5

2. PROPOSED RE-ELECTION OF RETIRING DIRECTORS 5

3. PROPOSED GRANT OF SHARE ISSUE MANDATE TO ISSUE SHARES 6

4. PROPOSED GRANT OF SHARE REPURCHASE MANDATE TO REPURCHASE SHARES 6

5. PROPOSED RE-APPOINTMENT OF THE AUDITOR 6

6. DECLARATION OF FINAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS 7

7. NOTICE OF ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT 7

8. RESPONSIBILITY STATEMENT 8

9. RECOMMENDATION 8

APPENDIX I – DETAILS OF DIRECTORS PROPOSED TO BE RE-ELECTED I-1

APPENDIX II – EXPLANATORY STATEMENT II-1

NOTICE OF ANNUAL GENERAL MEETING AGM-1

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"2022 Share Award Scheme"	the 2022 restricted share award scheme conditionally adopted by the Company on February 17, 2022 and amended by the Company on June 25, 2024, the principal terms of which are summarized in the circular of the Company dated May 31, 2024
"2025 Share Scheme"	the 2025 share scheme adopted by the Company on December 5, 2025, the principal terms of which are summarized in the circular of the Company dated November 19, 2025
"Annual General Meeting"	the annual general meeting of the Company to be held at Conference Room No. 3, 5th Floor, Chengdu Xinan Gynecology Hospital, 66 Bisheng Road, Jinjiang District, Chengdu, Sichuan, China on Thursday, June 25, 2026 at 9:00 a.m., or any adjournment thereof and notice of which is set out on pages AGM-1 to AGM-5 of this circular
"Articles of Association"	the fifth amended and restated articles of association of the Company adopted on June 25, 2024, as amended from time to time
"associate(s)"	has the meaning ascribed to it in the Listing Rules
"Board"	the board of Directors
"Cayman Islands Companies Act"	the Companies Act, Cap. 22 (Act 3 of 1961), as consolidated and revised from time to time) of the Cayman Islands
"CCASS"	the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited
"China" or the "PRC"	the People's Republic of China, and for the purpose of this circular only, excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"Company"	Jinxin Fertility Group Limited (錦欣生殖醫療集團有限公司*), an exempted company established in the Cayman Islands with limited liability on May 3, 2018
"core connected person(s)"	has the meaning ascribed to it in the Listing Rules
"Director(s)"	the director(s) of the Company
"Final Dividend'	a final dividend of HK$4.18 cents per Share in respect of the year ended December 31, 2025

"Group"	the Company and its subsidiaries
"HK$"	Hong Kong dollar, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Latest Practicable Date"	May 26, 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Nomination Committee"	the nomination committee of the Board
"Prospectus"	the prospectus issued by the Company dated June 13, 2019
"Remuneration Committee"	the remuneration committee of the Board
"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	ordinary share(s) in the capital of the Company with nominal value of US$0.00001 each, which include treasury Share(s), if any (for the avoidance of doubt, the holders of treasury Shares have no voting rights at the general meeting(s) of the Company)
"Share Issue Mandate"	a general mandate proposed to be granted to the Directors at the Annual General Meeting to allot, issue and/or deal with additional Shares (including any sale or transfer of treasury Shares) not exceeding 20% of the total number of issued Shares (excluding treasury Shares) as at the date of passing of the relevant resolution granting the Share Issue Mandate
"Share Repurchase Mandate"	a general mandate proposed to be granted to the Directors at the Annual General Meeting to repurchase Shares not exceeding 10% of the total number of the issued Shares (excluding any treasury Shares) as at the date of passing of the relevant resolution granting the Share Repurchase Mandate
"Shareholder(s)"	the holder(s) of the Share(s)
"Share Scheme(s)"	share scheme(s) involving issuance of new Shares adopted and to be adopted by the Company from time to time

"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Takeovers Code"	the Code on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission of Hong Kong, as amended from time to time
"treasury Shares"	has the meaning ascribed to it under the Listing Rules
"US$"	United States dollar, the lawful currency of the United States of America
"%"	per cent

* *For identification purpose only*

Jinxin Fertility Group Limited
錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

Executive Directors:
Mr. Dong Yang *(Chief Executive Officer and Acting Chief Financial Officer)*
Dr. Lyu Rong *(Co-chief Executive Officer)*
Dr. Geng Lihong

Non-executive Directors:
Mr. Zhong Yong *(Chairman)*
Ms. Hu Zhe
Ms. Yan Xiaoqing
Mr. Chen Shuyun

Independent Non-executive Directors:
Dr. Chong Yat Keung
Dr. Li Jianwei
Mr. Wang Xiaobo
Mr. Ye Changqing

Registered office:
Vistra (Cayman) Limited
P.O. Box 31119 Grand Pavilion
Hibiscus Way, 802 West Bay Road
Grand Cayman
KY1-1205
Cayman Islands

Headquarters and principal place of business in the PRC:
No. 301, North Jingsha Road
Jinjiang District, Chengdu
Sichuan, China

Principal place of business in Hong Kong:
Unit No. 1907B
Level 19, International Commerce Centre,
1 Austin Road West, Kowloon
Hong Kong

June 2, 2026

To the Shareholders

Dear Sir or Madam

(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS
(2) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES
(3) DECLARATION OF FINAL DIVIDEND
(4) PROPOSED RE-APPOINTMENT OF AUDITOR
AND
(5) NOTICE OF ANNUAL GENERAL MEETING

* *For identification purpose only*

1. INTRODUCTION

The purpose of this circular is to provide the Shareholders with further information, among other things, on the resolutions to be proposed at the Annual General Meeting: (i) the proposed re-election of the retiring Directors; (ii) the proposed grant of the Share Issue Mandate and the Share Repurchase Mandate; (iii) the declaration of the Final Dividend; and (iv) the re-appointment of the auditor of the Company.

2. PROPOSED RE-ELECTION OF RETIRING DIRECTORS

In accordance with Article 84(1) of the Articles of Association, one-third of the Directors for the time being (or, if their number is not a multiple of three, then the number nearest to but not less than one-third) will retire from office by rotation and will be eligible for re-election and re-appointment at every annual general meeting, provided that every Director shall be subject to retirement by rotation at least once every three years.

Accordingly, Dr. Geng Lihong, Ms. Yan Xiaoqing, Dr. Chong Yat Keung and Mr. Wang Xiaobo shall retire by rotation as Directors at the Annual General Meeting and, being eligible, will offer themselves for re-election at the Annual General Meeting.

Dr. Chong Yat Keung and Mr. Wang Xiaobo, being the independent non-executive Directors, have confirmed their independence with reference to the factors set out in Rule 3.13 of the Listing Rules.

Each of Dr. Chong Yat Keung and Mr. Wang Xiaobo has confirmed that they will continue to devote sufficient time for discharge of their functions and responsibilities as an independent non-executive Director. With their background and experience, Dr. Chong Yat Keung and Mr. Wang Xiaobo are fully aware of the responsibilities and expected time involvement in the Company.

To ensure that the Board has a balance of skills, knowledge, experience and diversity of perspectives appropriate to the Company's business needs and development, the Nomination Committee has reviewed the structure and composition of the Board, the confirmations and disclosures given by the retiring Directors, their qualifications, skills and experience, time commitment and contribution with reference to the nomination principles and criteria set out in the Company's Board diversity policy and nomination policy and the Company's corporate strategy. Therefore, the Nomination Committee has recommended to the Board, and the Board has accepted such recommendation, on the re-election of Dr. Geng Lihong, Ms. Yan Xiaoqing, Dr. Chong Yat Keung and Mr. Wang Xiaobo, who are due to retire at the Annual General Meeting, as executive, non-executive and independent non-executive Directors, respectively.

The Nomination Committee has nominated and the Board has recommended Dr. Geng Lihong, Ms. Yan Xiaoqing, Dr. Chong Yat Keung and Mr. Wang Xiaobo to stand for re-election at the Annual General Meeting.

Details of the above retiring Directors who are subject to re-election at the Annual General Meeting are set out in Appendix I to this circular in accordance with the relevant requirements of the Listing Rules.

3. PROPOSED GRANT OF SHARE ISSUE MANDATE TO ISSUE SHARES

In order to ensure flexibility and give discretion to the Directors, in the event that it becomes desirable for the Company to issue any new Shares, approval is to be sought from the Shareholders, pursuant to the Listing Rules, for the Share Issue Mandate to issue Shares. At the Annual General Meeting, an ordinary resolution numbered 6(A) will be proposed to grant the Share Issue Mandate to the Directors to exercise the powers of the Company to allot, issue and deal with additional Shares (including any sale or transfer of treasury Shares) not exceeding 20% of the total number of issued Shares (excluding any treasury Shares) as at the date of passing of the proposed resolution in relation to the Share Issue Mandate.

As at the Latest Practicable Date, 2,705,044,043 Shares have been fully paid (of which 35,048,500 Shares were repurchased but not cancelled by the Company as of the Latest Practicable Date). Subject to the passing of the ordinary resolution numbered 6(A) and on the basis that no further Shares are issued or repurchased after the Latest Practicable Date and up to the date of the Annual General Meeting, the Company will be allowed to issue a maximum of 533,999,108 Shares.

In addition, subject to a separate approval of the ordinary resolution numbered 6(C), the number of Shares purchased by the Company under ordinary resolution numbered 6(B) will also be added to extend the Share Issue Mandate as mentioned in ordinary resolution numbered 6(A) provided that such additional value shall represent up to 10% of the total number of issued Shares (excluding any treasury Shares) as at the date of passing the proposed resolutions in relation to the Share Issue Mandate and Share Repurchase Mandate. The Directors wish to state that they have no immediate plans to exercise the Share Issue Mandate.

4. PROPOSED GRANT OF SHARE REPURCHASE MANDATE TO REPURCHASE SHARES

In addition, an ordinary resolution will be proposed at the Annual General Meeting to approve the grant of the Share Repurchase Mandate to the Directors to exercise the powers of the Company to repurchase Shares representing up to 10% of the total number of issued Shares (excluding any treasury Shares and Shares repurchased but not cancelled) as at the date of passing of the proposed resolution in relation to the Share Repurchase Mandate.

An explanatory statement required by the Listing Rules to be sent to the Shareholders in connection with the proposed Share Repurchase Mandate is set out in Appendix II to this circular. This explanatory statement contains all information reasonably necessary to enable the Shareholders to make an informed decision on whether to vote for or against the relevant resolution at the Annual General Meeting.

5. PROPOSED RE-APPOINTMENT OF THE AUDITOR

Deloitte Touche Tohmatsu will retire as the auditor of the Company at the Annual General Meeting and, being eligible, offer itself for re-appointment.

The Board proposed to re-appoint Deloitte Touche Tohmatsu as the auditor of the Company for the year ending December 31, 2026 and to hold office until the conclusion of the next annual general meeting of the Company.

The estimated audit fee payable to Deloitte Touche Tohmatsu for the interim review, annual audit and other audit related services for the consolidated financial statements of the Group for the financial year ending December 31, 2026, is expected to be in the range of approximately RMB4.36 million to RMB5.15 million. The estimated audit fee has been determined after due consideration and arm's length negotiations between the Company and Deloitte Touche Tohmatsu, taking into account, among other things, the size and structure of the Group, the nature and complexity of the Group's businesses, the expected scope, timetable and direction of the audit, and the time and resources deployed by the auditors. The estimated audit fee also assumes that there will be no material changes in the Group's operations, accounting policies, or regulatory environment during the financial year.

6. DECLARATION OF FINAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS

The Board has recommended the payment of a final dividend of HK$4.18 cents per Share in respect of the year ended December 31, 2025. Conditional upon the passing of ordinary resolution numbered 4 by the Shareholders at the Annual General Meeting to be held on Thursday, June 25, 2026, the register of members of the Company will be closed from Thursday, July 2, 2026 to Tuesday, July 7, 2026 (both dates inclusive) during which period no share transfers will be registered and the Final Dividend is expected to be paid on or before Tuesday, July 28, 2026. Shareholders appearing on the register of members of the Company at the close of business on Tuesday, July 7, 2026 will be entitled to the Final Dividend. The Final Dividend will be paid in Hong Kong dollars. In order to determine the identity of the Shareholders who are entitled to the Final Dividend, all transfers accompanied by the relevant share certificates must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Tuesday, June 30, 2026.

7. NOTICE OF ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

Set out on pages AGM-1 to AGM-5 of this circular is the notice of the Annual General Meeting at which, among other things, ordinary resolutions will be proposed to Shareholders to consider and approve (i) the re-election of the retiring Directors; (ii) the grant of the Share Issue Mandate to issue Shares and the Share Repurchase Mandate to repurchase Shares; (iii) the declaration of the Final Dividend; and (iv) the proposed re-appointment of auditor.

A form of proxy for use at the Annual General Meeting is enclosed with this circular. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.jxr-fertility.com). Whether or not you are able to attend the Annual General Meeting, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and return it to the Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for holding of the Annual General Meeting (i.e. before 9:00 a.m. on Tuesday, June 23, 2026) or any

adjournment thereof. Completion and return of the form of proxy will not prevent you from attending and voting in person at the Annual General Meeting and at any adjournment thereof if you so wish and, in such event the form of proxy shall be deemed to be revoked.

There is no Shareholder who has any material interest in the proposed resolutions regarding the Share Issue Mandate and the Share Repurchase Mandate, therefore none of the Shareholders is required to abstain from voting on such resolutions. Separately, holders of treasury Shares (if any) shall abstain from voting on matters that require Shareholders' approval at the Company's general meetings.

Pursuant to Rule 13.39(4) of the Listing Rules and Article 66(1) of the Articles of Association, any resolution put to the vote of the Shareholders at a general meeting shall be decided on a poll except where the chairman of the Annual General Meeting, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Accordingly, each of the resolutions set out in the notice will be taken by way of poll.

On a poll, every Shareholder present in person (or, in the case of a Shareholder being a corporation, by its duly authorized representative) or by proxy shall have one vote for every fully paid Share held. A Shareholder present in person (or, in the case of a Shareholder being a corporation, by its duly authorized representative) or by proxy who is entitled to more than one vote need not use all his/its votes or cast all his/its votes in the same way.

8. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

9. RECOMMENDATION

The Directors consider that the proposed resolutions for the (i) re-election of certain retiring Directors; (ii) the proposed grant of the Share Issue Mandate to issue Shares and the Share Repurchase Mandate to repurchase Shares; (iii) the declaration of the Final Dividend; and (iv) the re-appointment of auditor of the Company are in the interests of the Group and the Shareholders as a whole. The Directors therefore recommend the Shareholders to vote in favour of all the resolutions to be proposed at the Annual General Meeting.

Yours faithfully
By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director

The following are the particulars of the Directors (as required by the Listing Rules) proposed to be re-elected at the Annual General Meeting.

As at the Latest Practicable Date, none of the following Directors, save as disclosed herein, had any interest in Shares within the meaning of Part XV of the SFO.

Save as disclosed herein, none of the following Directors holds any position with the Company or any other member of the Group, or any directorships in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed herein, the following Directors are not otherwise related to any Directors, senior management, substantial Shareholders or controlling Shareholders (as defined in the Listing Rules).

Save as disclosed herein, there is no other matter in relation to the following Directors that needs to be brought to the attention of the Shareholders and there is no other information relating to the following Directors which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

(1) Dr. Geng Lihong – Executive Director

Dr. Geng Lihong (耿麗紅), aged 57, has been an executive Director since March 28, 2021. She has also been the chief medical quality control officer of the Company since February 21, 2020. She is mainly responsible for guiding the implementation of clinical work and medical quality control. Prior to joining the Group, from July 2018 to January 2020, she served as the clinical director of the IVF Center of the First Affiliated Hospital of Chongqing Medical University (重慶醫科大學附屬第一醫院生殖醫學中心). From December 2009 to March 2018, she worked at the IVF Center of Chengdu Xinan Gynecological Hospital (成都西囡婦科醫院生殖醫學中心) and was responsible for clinical practice and management work. From May 1994 to August 2006, Dr. Geng worked at the Department of Obstetrics and Gynecology of the Second Affiliated Hospital of Xinjiang Medical University (新疆醫科大學第二附屬醫院) and was responsible for clinical practice, scientific research and teaching. From December 1991 to April 1994, Dr. Geng worked at the Department of Obstetrics and Gynecology of the Barkol People's Hospital, Barkol, Xinjiang, Uygur Autonomous Region (新疆維吾爾自治 區巴里坤縣人民醫院).

Dr. Geng obtained a bachelor's degree in medicine from Xinjiang Medical School (新疆醫學院) (the predecessor of Xinjiang Medical University) in the PRC in July 1991 and a doctoral degree in medicine with a major in reproductive endocrinology and assisted reproductive technology from West China School of Medicine, Sichuan University (四川大學華西臨床醫學院) in the PRC in July 2009.

Dr. Geng has served as a member of the standing committee of the Reproductive Medicine and Reproductive Ethics Subcommittee of the China Healthy Birth Science Association (中國優生科學協會生殖醫學與生殖倫理學分會) since February 2019. Since October 2019, she has served as the vice chairman of the Reproductive Medicine Professional Committee of the Chongqing Medical Association (重慶市醫學會生殖醫學專業委員會). Since July 2018, she has served as a member of the first session of the Reproductive Immunology Subcommittee of the Chongqing Society of Immunology (重慶市免疫學會生殖免疫分會). Since September 2017, she has served as a member of

the standing committee of the Reproductive Endocrinology Professional Committee of the China Medicine Education Association (中國醫藥教育協會生殖內分泌專業). Since July 2016, she has served as a member of the second session of the standing committee of the Reproductive Medicine Professional Committee of Sichuan Provincial Medical Association (四川省醫學會生殖醫學專業委員會). Dr. Geng was one of the main breeders of the first successful IVF in Tibet Autonomous Region and she was awarded "Excellent Expert with Outstanding Contributions" in Sichuan Province in 2018.

Dr. Geng has entered into a service contract with the Company for a term of three years with effect from her date of appointment until terminated in accordance with the terms and conditions of the service contract, and she is subject to the provisions of retirement by rotation and re-election of Directors under the Articles of Association. As an employee of the Group, Dr. Geng is entitled to a remuneration in the sum of RMB600,000 per annum, with bonus payable at the discretion of the Board, as determined by the Board with reference to her duties, relevant experience, workload and time devoted to the Group. The Board and the Remuneration Committee have determined that for the time being no additional emoluments will be payable to Dr. Geng in taking on additional responsibility as Director.

Save as disclosed above, Dr. Geng has not held directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the three years immediately preceding the Latest Practicable Date.

As of the Latest Practicable Date, Dr. Geng was interested in 120,000 Shares and 480,000 restricted shares granted to her under the 2022 Restricted Share Award Scheme entitling her to receive 480,000 shares upon vesting within the meaning of Part XV of the SFO.

(2) Ms. Yan Xiaoqing – Non-executive Director

Ms. Yan Xiaoqing (嚴曉晴), aged 56, has been a non-executive Director of the Company since March 28, 2021. She has also been a senior vice president of the Company since September 12, 2018. Her main responsibilities include the overall management of the Group and overseeing operations and internal audit matters. She joined the Group in March 2010 and served as an executive Director from May 3, 2018 to June 29, 2020. From March 2010 to October 2015, she served as the finance director of Chengdu Xinan Gynecological Hospital (成都西囡婦科醫院) and continued to be the finance director of Chengdu Xinan Clinic until October 2018. Between November 2006 and January 2010, Ms. Yan acted as the head of finance at Jinjiang District Maternity and Child Health Hospital and from February 2000 to January 2006, she was employed as an accountant. Prior to joining our Group, from January 1992 to January 2000, she worked at Luzhou Baoguang Pharmaceutical Company (瀘州寶光醫藥公司).

Ms. Yan obtained a college graduation certificate in law by way of distance learning from the correspondence college of Sichuan Province Party School of the Communist Party of China (中共四川省委黨校) in the PRC in June 2001 and a master's degree (correspondence course) in business administration from Open University of Hong Kong (香港公開大學) (now Hong Kong Metropolitan University (香港都會大學)) in November 2015.

Ms. Yan has entered into a service contract with the Company for a term of three years with effect from her date of appointment until terminated in accordance with the terms and conditions of the service contract, and she is subject to the provisions of retirement by rotation and re-election of Directors under the Articles of Association. As an employee of the Group, Ms. Yan is entitled to a remuneration in the sum of RMB600,000 per annum, with bonus payable at the discretion of the Board, as determined by the Board with reference to her duties, relevant experience, workload and time devoted to the Group. The Board and the Remuneration Committee have determined that for the time-being no additional emoluments will be payable to Ms. Yan in taking on additional responsibility as Director.

Save as disclosed above, Ms. Yan has not held directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the three years immediately preceding the Latest Practicable Date.

As of the Latest Practicable Date, Ms. Yan was interested in 3,016,000 Shares, 300,000 underlying shares in respect of share options granted to her under the 2025 Share Scheme and 150,000 restricted shares granted to her under the 2025 Share Scheme entitling her to receive 150,000 Shares upon vesting within the meaning of Part XV of the SFO. As of the Latest Practicable Date, Ms. Yan also held 51% of the equity interest in Chengdu Jinrun Fude Medical Management Company Limited (成都錦潤福德醫療管理 有限公司) ("**Jinrun Fude**"), an associated corporation (within the meaning of Part XV of the SFO) of the Company. Jinrun Fude is a subsidiary of the Group by virtue of the Contractual Arrangements (as defined in the annual report of the Company for year ended December 31, 2025).

(3) Dr. Chong Yat Keung – Independent non-executive Director

Dr. Chong Yat Keung (莊一強), aged 61, has been an independent non-executive Director of the Company since June 3, 2019. He is primarily responsible for supervising and providing independent judgment to the Board.

Dr. Chong has over 25 years of experience in the medical industry. From April 2015 to June 2020, he was an independent non-executive director of Wenzhou Kangning Hospital Co., Ltd. (HKEx stock code: 2120). From February 2012 to February 2015, Dr. Chong served as the deputy secretary-general of the Chinese Hospital Association (中國醫院協會). From January 2004 to January 2012 and since February 2015, he was the president of Guangzhou Ailibi Management Consulting Co., Ltd (廣州艾力彼管理顧問有限公司), a company engaged in the provision of hospital consultation services. From November 1994 to May 2000, he held various positions at a number of pharmaceutical companies including AstraZeneca Pharmaceutical Co., Ltd (阿斯利康製藥有限公司) and Beijing Novartis Pharmaceuticals Co., Ltd (北京諾華製藥有限公司), where he was primarily responsible for the sales and marketing of pharmaceutical drugs.

Dr. Chong graduated with a bachelor's degree in medical science from Zhongshan Medical University (中山醫科大學), subsequently merged into Sun Yat-Sen University (中山大學) in Guangzhou in July 1986. He also obtained a master's degree in business administration degree from Northwestern

University and Hong Kong University of Science and Technology in May 2004. He also graduated with a doctoral degree in management from ISCTE – University Institute of Lisbon in November 2013.

Dr. Chong has signed an appointment letter with the Company for a term of three years with effect from his date of appointment until terminated in accordance with the terms and conditions of appointment letter, and he is subject to the provisions of retirement by rotation and re-election of Directors under the Articles of Association. He is entitled to a remuneration of HK$300,000 per annum as determined by the Board with reference to his duties, relevant experience, workload and time devoted to the Group.

Save as disclosed above, Dr. Chong has not held directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the three years immediately preceding the Latest Practicable Date.

As of the Latest Practicable Date, Dr. Chong was interested in 300,000 underlying shares in respect of share options granted to him under the 2025 Share Scheme and 150,000 restricted shares granted to him under the 2025 Share Scheme entitling him to receive 150,000 Shares upon vesting within the meaning of Part XV of the SFO.

(4) Mr. Wang Xiaobo – Independent non-executive Director

Mr. Wang Xiaobo (王嘯波), aged 50, has been an independent non-executive Director of the Company since June 3, 2019. He is primarily responsible for supervising and providing independent judgment to the Board.

Mr. Wang has over 20 years of experience in the legal service industry with a focus on corporate law. In April 2000, Mr. Wang joined Duan & Duan Law Firm (段和段律師事務所) and is currently acting as the executive chairman, chief executive officer and partner. He has been an independent non-executive director of Shanghai Tunnel Engineering Co., Ltd. (上海隧道工程股份有限公司) (SSE stock code: 600820) from December 2018 to January 2025 and Juneyao Airlines Co., Ltd. (上海吉祥航空股份有限公司) (SSE stock code: 603885) since July 2017. He has been an independent director of Hengyi Biomedical Technology (Shanghai) Co Ltd (恒翼生物醫藥 (上海) 股份有限公司) since November 2021.

Mr. Wang received a bachelor's degree in literature from Shanghai International Studies University (上海外國語大學) in the PRC in January 1997 and another bachelor's degree in law from Shanghai University (上海大學) in the PRC in July 1999. Mr. Wang also graduated from the University of Oxford with a master's degree in law in the United Kingdom in October 2005. Mr. Wang received his PRC lawyer's practicing license issued by the Shanghai Bureau of Justice (上海市司法局) in January 2001.

Mr. Wang has signed an appointment letter with the Company for a term of three years with effect from his date of appointment until terminated in accordance with the terms and conditions of appointment letter, and he is subject to the provisions of retirement by rotation and re-election of

Directors under the Articles of Association. He is entitled to a remuneration of HK$300,000 per annum as determined by the Board with reference to his duties, relevant experience, workload and time devoted to the Group.

Save as disclosed above, Mr. Wang has not held directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the three years immediately preceding the Latest Practicable Date.

As of the Latest Practicable Date, Mr. Wang was interested in 300,000 underlying shares in respect of share options granted to him under the 2025 Share Scheme and 150,000 restricted shares granted to him under the 2025 Share Scheme entitling him to receive 150,000 Shares upon vesting within the meaning of Part XV of the SFO.

The following is an explanatory statement required to be sent to the Shareholders under the Listing Rules in connection with the proposed Share Repurchase Mandate.

SHARE CAPITAL

As at the Latest Practicable Date, the number of issued Shares was 2,705,044,043 Shares of nominal value of US$0.00001 each which have been fully paid (of which 35,048,500 Shares were repurchased but not cancelled by the Company as of the Latest Practicable Date). Subject to the passing of the proposed resolution granting the Share Repurchase Mandate and on the basis that no further Shares are issued or repurchased before the Annual General Meeting, the Company will be allowed to repurchase a maximum of 266,999,554 Shares which represent 10% of the total number of issued Shares (excluding treasury Shares and Shares repurchased but not cancelled by the Company) during the period ending on the earlier of (i) the conclusion of the next annual general meeting of the Company; or (ii) the expiry of the period within which the next annual general meeting of the Company is required by any applicable laws or the Articles of Association to be held; or (iii) the passing of an ordinary resolution by Shareholders in general meeting of the Company revoking or varying such mandate.

If the Company repurchases Shares pursuant to the Share Repurchase Mandate, the Company may either (i) cancel the repurchased Shares and/or (ii) hold such Shares in treasury, subject to market conditions and the capital management needs of the Company at the relevant time such repurchases of Shares are made. If the Company holds Shares in treasury, any sale or transfer of treasury Shares will be subject to the terms of the Share Issue Mandate and made in accordance with the Listing Rules and applicable laws and regulations of the Cayman Islands.

To the extent that any treasury Shares are deposited with CCASS pending resale on the Stock Exchange, the Company will adopt appropriate measures to ensure that it does not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as treasury Shares. The Company (i) will not (or will procure its broker not to) give any instructions to Hong Kong Securities Clearing Company Limited to vote at general meetings for the treasury Shares deposited with CCASS and (ii) in the case of dividends or distributions, the Company will withdraw the treasury Shares from CCASS, and either re-register them in its own name as treasury Shares or cancel them, in each case before the record date for the dividends or distributions.

REASONS FOR AND FUNDING OF REPURCHASES

The Directors believe that it is in the best interests of the Company and the Shareholders to have a general authority from the Shareholders to enable the Company to repurchase its Shares in the market. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the Company's net asset value and/or its earnings per Share and will only be made when the Directors believe that such repurchases will benefit the Company and the Shareholders as a whole.

Repurchase of the Shares must be funded out of funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands. The Directors may not repurchase the Shares on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange. Subject to the foregoing, the Directors may make repurchases with profits of the Company, the share premium of the Company or out of proceeds of a fresh

issuance of shares made for the purpose of the repurchase or, if authorized by the Articles of Association and subject to the Cayman Islands Companies Act, out of capital. The amount of premium payable on the repurchase of Shares may only be paid out of either or both profits of the Company or from sums standing to the credit of the share premium account of the Company or, subject to the Cayman Islands Companies Act, out of capital of the Company.

In addition, under the laws of the Cayman Islands, payment out of capital by a company for the purchase by a company of its own shares is unlawful unless immediately following the date on which the payment is proposed to be made, the company shall be able to pay its debts as they fall due in the ordinary course of business. In accordance with the laws of the Cayman Islands, the shares so bought back would be treated as cancelled but the aggregate amount of authorised share capital would not be reduced.

The Directors have no present intention to repurchase any Shares and they would only exercise the powers to repurchase pursuant to the proposed resolution numbered 6(B) in the notice of the Annual General Meeting in accordance with the Listing Rules and the laws of the Cayman Islands and in circumstances where they consider that the repurchase would be in the best interests of the Company. The Directors believe that if the Share Repurchase Mandate is exercised in full, it may not have a material adverse impact on the working capital or gearing position of the Company, as compared with the positions disclosed in the audited consolidated financial statements of the Company as at December 31, 2025, being the date to which the latest published audited consolidated financial statements of the Company were made up. The Directors do not propose to exercise the Share Repurchase Mandate to such an extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or its gearing levels which, in the opinion of the Directors, are from time to time appropriate for the Company.

GENERAL

None of the Directors nor, to the best of their knowledge, having made all reasonable enquiries, their respective close associates (as defined in the Listing Rules), have any present intention if the Share Repurchase Mandate is approved by the Shareholders, to sell any Shares to the Company.

The Directors will exercise the Share Repurchase Mandate in accordance with the Listing Rules, the Articles of Association and the applicable laws of the Cayman Islands. In addition, the Company has confirmed that neither the explanatory statement nor the proposed share repurchase has any unusual features.

No core connected person (as defined in the Listing Rules) has notified the Company that he or she has a present intention to sell any Shares to the Company, or has undertaken not to do so, if the Share Repurchase Mandate is approved by the Shareholders.

TAKEOVERS CODE

If as a result of a repurchase of Shares pursuant to the Share Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder, or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby

become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code. Save as aforesaid, the Directors are not aware of any consequences which would arise under the Takeovers Code as a result of any repurchase of Shares pursuant to the Share Repurchase Mandate.

As at the Latest Practicable Date, to the best knowledge and belief of the Directors, JINXIN Fertility Investment Group Limited is deemed to be interested in 319,471,061 Shares, representing approximately 11.81% of the issued Shares. In the event that the Directors should exercise in full the Share Repurchase Mandate, such interests will be increased to approximately 13.10% of the issued Shares.

To the best knowledge and belief of the Directors, such increase would not give rise to an obligation to make a mandatory offer under the Takeovers Code. The Directors have no present intention to repurchase the Shares to the extent that will trigger the obligations under the Takeovers Code for JINXIN Fertility Investment Group Limited to make a mandatory offer. The Directors are not aware of any other consequences which may arise under the Takeovers Code as a result of any purchase by the Company of its Shares.

The Listing Rules prohibit a company from making repurchase on the Stock Exchange if the result of the repurchase would be that less than 25% (or such other prescribed minimum percentage as determined by the Stock Exchange) of the total number of issued shares of the Company would be in public hands. The Directors do not propose to repurchase Shares which would result in less than the prescribed minimum percentage of Shares in public hands.

SHARE REPURCHASE MADE BY THE COMPANY

The Company had repurchased a total of 74,710,500 Shares on the Stock Exchange during the six months preceding the Latest Practicable Date, of which 39,662,000 Shares had been cancelled and 35,048,500 Shares have not yet been cancelled as at the Latest Practicable Date. Details of which are as follows:

Date of Repurchase	No. of Shares repurchased	Highest price paid per Share *HK$*	Lowest price paid per Share *HK$*
December 5, 2025	7,722,000	2.58	2.55
December 8, 2025	5,928,500	2.58	2.47
December 9, 2025	3,802,000	2.50	2.40
December 10, 2025	1,925,500	2.49	2.43
December 11, 2025	3,846,000	2.53	2.43
December 12, 2025	7,722,000	2.53	2.46
December 15, 2025	3,891,000	2.57	2.53
December 17, 2025	4,825,000	2.53	2.47
March 27, 2026	3,517,500	2.31	2.26
March 30, 2026	833,500	2.33	2.30
March 31, 2026	1,955,000	2.37	2.35
April 10, 2026	3,200,000	2.47	2.44
April 15, 2026	2,066,000	2.40	2.39
April 20, 2026	3,225,000	2.45	2.43
April 21, 2026	803,000	2.47	2.45
April 28, 2026	2,066,000	2.42	2.38
April 30, 2026	2,000,000	2.40	2.39
May 8, 2026	3,278,500	2.42	2.39
May 13, 2026	3,265,000	2.43	2.38
May 14, 2026	3,292,000	2.40	2.37
May 15, 2026	1,244,500	2.38	2.38
May 19, 2026	1,139,500	2.35	2.34
May 21, 2026	1,293,000	2.29	2.28
May 22, 2026	1,870,000	2.26	2.25

SHARE PRICES

The highest and lowest prices at which the Shares were traded on the Stock Exchange during each of the previous 12 months preceding the Latest Practicable Date were as follows:

Month	Highest prices	Lowest prices
	HK$	*HK$*
2025		
May	3.03	2.68
June	3.20	2.61
July	3.70	2.90
August	3.61	2.86
September	2.98	2.61
October	2.90	2.45
November	2.62	2.33
December	2.61	2.36
2026		
January	2.67	2.36
February	2.55	2.38
March	2.54	2.09
April	2.53	2.35
May (up to the Latest Practicable Date)	2.44	2.22

Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the annual general meeting (the "**Meeting**") of **Jinxin Fertility Group Limited** (the "**Company**") will be held at Conference Room No. 3, 5th Floor, Chengdu Xinan Gynecology Hospital, 66 Bisheng Road, Jinjiang District, Chengdu, Sichuan, China on Thursday, June 25, 2026 at 9:00 a.m. for the following purposes:

Ordinary Resolutions

1. To receive and adopt the audited consolidated financial statements of the Company for the year ended December 31, 2025 and the reports of the directors and auditor thereon.

2. To re-elect the following retiring directors of the Company, each as a separate resolution:

   (i) Dr. Geng Lihong as an executive director;

   (ii) Ms. Yan Xiaoqing as a non-executive director;

   (iii) Dr. Chong Yat Keung as an independent non-executive director; and

   (iv) Mr. Wang Xiaobo as an independent non-executive director.

3. To authorize the board of directors of the Company (the "**Board**") to fix the remuneration of the directors of the Company.

4. To declare a final dividend of HK$4.18 cents per share for the year ended December 31, 2025.

5. To re-appoint Deloitte Touche Tohmatsu as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending December 31, 2026.

* *For identification purpose only*

6. To consider and, if thought fit, pass with or without modification the following resolutions as ordinary resolutions:

(A) "**That:**

(i) subject to paragraph (iii) below, the exercise by the directors of the Company during the Relevant Period (as defined hereinafter) of all the powers of the Company to allot, issue and/or otherwise deal with additional shares of the Company or securities convertible into shares, or options, warrants or similar rights to subscribe for shares or such convertible securities of the Company and to make or grant offers, agreements and/or options (including bonds, warrants and debentures convertible into shares of the Company) which may require the exercise of such powers, be and is hereby generally and unconditionally approved;

(ii) the approval in paragraph (i) above shall be in addition to any other authorization given to the directors of the Company and shall authorize the directors of the Company during the Relevant Period (as defined hereinafter) to make or grant offers, agreements and/or options which may require the exercise of such power after the end of the Relevant Period;

(iii) the aggregate number of shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) by the directors of the Company during the Relevant Period (as defined hereinafter) pursuant to paragraph (i) above, otherwise than pursuant to paragraph (i) of this resolution, otherwise than pursuant to:

(a) any Rights Issue (as defined hereinafter);

(b) the grant or exercise of any option under any share option scheme of the Company (if applicable) or any other option, scheme or similar arrangements for the time being adopted for the grant or issue to the directors of the Company, officers and/or employees of the Company and/or any of its subsidiaries and/or other eligible participants specified thereunder of options to subscribe for Shares or rights to acquire Shares;

(c) the vesting of restricted shares and restricted share units granted or to be granted pursuant to the share award schemes of the Company;

(d) any scrip dividend or similar arrangement providing for the allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company; or

(e) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any existing convertible notes issued by the Company or any existing securities of the Company which carry rights to subscribe for or are convertible into Shares, shall not exceed the aggregate of:

(I) 20% of the total number of issued shares of the Company (excluding treasury shares of the Company) as at the date of passing this resolution; and

(II) (if the Board is so authorized by resolution numbered 6(C)) the aggregate number of shares of the Company repurchased by the Company subsequent to the passing of resolution numbered 6(B) (up to a maximum equivalent to 10% of the total number of issued shares of the Company (excluding treasury shares of the Company) as at the date of passing resolution numbered 6(B))),

and the approval shall be limited accordingly; and

(iv) for the purpose of this resolution:

(a) "Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(I) the conclusion of the next annual general meeting of the Company;

(II) the expiry of the period within which the next annual general meeting of the Company is required by any applicable laws or the articles of association of the Company to be held; or

(III) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the directors of the Company by this resolution;

(b) "Rights Issue" means an offer of shares of the Company or an issue of warrants, options or other securities giving rights to subscribe for shares of the Company, open for a period fixed by the directors of the Company to holders of shares of the Company on the register of members on a fixed record date in proportion to their then holdings of such shares of the Company (subject to such exclusions or other arrangements as the directors of the Company may deem necessary or expedient in relation to fractional entitlements or, having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the exercise or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, any recognised regulatory body or any stock exchange applicable to the Company); and

(c) Any reference to an allotment, issue, grant, offer or disposal of shares of the Company shall include the sale or transfer of treasury shares of the Company (including to satisfy any obligation upon the conversion or exercise of any convertible securities, warrants, options or similar rights to subscribe for shares in the Company) to the extent permitted by, and subject to the provisions of, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and applicable laws and regulations."

(B) "**That:**

(i) subject to paragraph (ii) of this resolution, the exercise by the directors of the Company during the Relevant Period (as defined hereinafter) of all the powers of the Company to repurchase shares of the Company on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") or on any other stock exchange on which the shares of the Company may be listed and which is recognised for this purpose by the Securities and Futures Commission and the Stock Exchange under the Code on Share Buy-backs and, subject to and in accordance with all applicable laws and the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), be and is hereby generally and unconditionally approved;

(ii) the aggregate number of the shares to be repurchased pursuant to the approval in paragraph (i) of this resolution shall not exceed 10% of the total number of issued shares of the Company (excluding any treasury shares of the Company) as at the date of passing of this resolution, and the said approval shall be limited accordingly;

(iii) subject to the passing of each of the paragraphs (i) and (ii) of this resolution, any prior approvals of the kind referred to in paragraphs (i) and (ii) of this resolution which had been granted to the directors of the Company and which are still in effect be and are hereby revoked; and

(iv) for the purpose of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(a) the conclusion of the next annual general meeting of the Company;

(b) the expiry of the period within which the next annual general meeting of the Company is required by any applicable laws or the articles of association of the Company to be held; or

(c) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the directors of the Company by this resolution."

(C) "**That:**

(i) conditional upon the resolutions numbered 6(A) and 6(B) set out in this notice being passed, the general mandate granted to the directors of the Company to exercise the powers of the Company to allot, issue and/or otherwise deal with new shares of the Company and to make or grant offers, agreements and options which might require the exercise of such powers pursuant to the resolution numbered 6(A) set out in this notice be and is hereby extended by the addition to the number of the issued shares of the Company which may be allotted or agreed conditional or unconditionally to be allotted by the directors of the Company pursuant to such general mandate of an amount representing the number of the issued shares of the Company repurchased and subsequently cancelled by the Company under the authority granted pursuant to resolution numbered 6(B) set out in this notice, provided that such extended amount shall represent up to 10% of the number of issued shares of the Company (excluding any treasury shares of the Company) as at the date of passing of the said resolutions; and

(ii) for the purpose of this Resolution, any reference to an allotment, issue, grant, offer or disposal of shares of the Company shall include the sale or transfer of treasury shares of the Company (including to satisfy any obligation upon the conversion or exercise of any convertible securities, warrants, options or similar rights to subscribe for shares in the Company) to the extent permitted by, and subject to the provisions of, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and applicable laws and regulations."

Yours faithfully
By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director

Hong Kong, June 2, 2026

Registered Office:
Vistra (Cayman) Limited
P.O. Box 31119 Grand Pavilion
Hibiscus Way, 802 West Bay Road
Grand Cayman
KY1-1205
Cayman Islands

Headquarters and principal place of business in the PRC:
No. 301, North Jingsha Road
Jinjiang District, Chengdu
Sichuan, China

Principal place of business in Hong Kong:
Unit No. 1907B
Level 19, International Commerce Centre,
1 Austin Road West, Kowloon
Hong Kong

Notes:

(i) All resolutions at the Meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of The Stock Exchange of Hong Kong Limited and the Company in accordance with the Listing Rules.

(ii) A shareholder entitled to attend and vote at the Meeting is entitled to appoint one or more proxies to attend, speak and vote in his/her stead. The proxy does not need to be a shareholder of the Company.

(iii) Where there are joint registered holders of any shares, any one of such persons may vote at the Meeting (or at any adjournment of it), either personally or by proxy, in respect of such shares as if he/she were solely entitled thereto but the vote of the senior holder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the vote(s) of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the relevant joint holding.

(iv) In order to be valid, the completed form of proxy, must be deposited at the Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong together with the power of attorney or other authority (if any) under which it is signed or a certified copy of that power of attorney or authority (such certification to be made by either a notary public or a solicitor qualified to practice in Hong Kong), at least 48 hours before the time appointed for holding the Meeting or any adjournment thereof (as the case may be). The completion and return of the form of proxy shall not preclude shareholders of the Company from attending and voting in person at the above meeting (or any adjourned meeting thereof) if they so wish.

(v) The register of members of the Company will be closed from Monday, June 22, 2026 to Thursday, June 25, 2026, both days inclusive, in order to determine the eligibility of shareholders to attend the above meeting, during which period no share transfers will be registered. To be eligible to attend the Meeting, all properly completed transfer forms accompanied by the relevant share certificates must be lodged for registration with the Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Thursday, June 18, 2026. The record date for the attending and voting at the Meeting is Thursday, June 25, 2026.

(vi) The register of members of the Company will be closed from Thursday, July 2, 2026 to Tuesday, July 7, 2026, both days inclusive, in order to determine the entitlement of shareholders to receive the final dividend of the Company, during which period no share transfers will be registered. To qualify for the final dividend, all properly completed transfer forms accompanied by the relevant share certificates must be lodged for registration with the Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Tuesday, June 30, 2026.